LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
Last trade$5.18
Day change-$0.11 (-2.08%)
Day range$5.17 – $5.40
Volume88,497
Market cap$65M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$65.04M
Price / earnings
4.19×
Price / book
4.36×
Price / sales
1.08×
EV / sales
0.92×
EV / EBITDA
-15.53×
Profitability
Earnings per share
$1.26
Return on assets
22.3%
Return on equity
104.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.25×
Current ratio
2.39×
Quick ratio
1.13×
Cash ratio
0.69×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LNSR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$16.5M
$13.43M
$16.03M
$14.32M
$13.94M
$14.16M
$16.73M
$13.54M
Cost of revenue
$6.72M
$7.05M
$9.09M
$8.28M
$6.91M
$7.03M
$9.62M
$7.27M
Gross profit
$9.78M
$6.38M
$6.94M
$6.04M
$7.02M
$7.13M
$7.11M
$6.27M
Selling, general and administrative
$6.14M
$2.53M
$10.33M
$12.02M
$11.66M
$11.15M
$6.83M
$6.08M
Research and development
$1.27M
$1.39M
$1.3M
$1.37M
$1.43M
$1.53M
$1.34M
$1.2M
Total operating expenses
$7.64M
$4.14M
$11.86M
$13.62M
$13.31M
$12.92M
$8.4M
$7.51M
Operating income
$2.13M
$2.24M
-$4.92M
-$7.58M
-$6.29M
-$5.79M
-$1.29M
-$1.25M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$3.54M
$36.33M
-$1.46M
-$3.71M
-$1.76M
-$27.35M
-$18.7M
-$1.5M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$3.54M
$36.33M
-$1.46M
-$3.71M
-$1.76M
-$27.35M
-$18.7M
-$1.5M
Net income attributable to common shareholders
$1.77M
$18.91M
-$1.46M
-$3.71M
-$1.76M
-$27.35M
-$18.7M
-$1.5M
EBITDA
$3.24M
$3.37M
-$3.75M
-$6.42M
-$5.19M
-$4.71M
-$184K
-$239K
Basic earnings per share
$0.14
$1.56
-$0.12
-$0.31
-$0.15
-$2.32
-$1.61
-$0.13
Diluted earnings per share
$0.10
$0.00
-$0.12
-$0.31
-$0.15
-$2.32
-$1.61
-$0.13
Recent news
Company coverage with links to the original publishers.
Alcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.
LENSAR, Inc. announced the termination of its merger agreement with Alcon Research, LLC due to FTC opposition. The companies mutually agreed that obtaining necessary U.S. regulatory approvals was unlikely by the merger's outside date. LENSAR will retain the $10.0 million deposit and plans to focus on expanding its ALLY Robotic Cataract Laser System globally. Financial results and go-forward strategy details will be shared on March 31, 2026.
LENSAR, Inc. announced that its pending acquisition by Alcon Research, LLC remains under FTC review following a Second Request for Additional Information. The company expects to close the transaction in the first half of 2026, subject to regulatory approval and satisfaction of closing conditions.
SpyGlass Pharma announced the appointment of Elizabeth O'Farrell to its Board of Directors, bringing over 30 years of healthcare industry experience. She will serve as an Independent Director and Chair of the Audit Committee, supporting the company's advancement of its Drug Delivery Platform for glaucoma management.
LENSAR reported strong Q2 2025 performance with 18 ALLY Robotic Cataract Laser Systems placed, 23% increase in worldwide procedure volumes, and continued progress on its proposed merger with Alcon. Total revenue increased 10% to $13.9 million, with net loss improving to $1.8 million.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.